Immunotherapy of malignant ascites with trifunctional antibodies
Open accessAbstract
A new class of intact bispecific antibodies shows unmet effector qualities by activation of not only T cells but also simultaneous activation of Fcγ receptor type I/III+ cells (macrophages, NK‐cells and DC). These trifunctional antibodies (trAb) lead to efficient specific killing of targeted tumor cells without any pre‐ or co‐stimulation. This concept was investigated in vivo in patients with malignant ascites in a clinical situation that allowed monitoring of tumor cell elimination and correlation with clinical effects. In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM‐ or Her2/neu‐antigen on tumor cells. Treatment consisted of 4–6 applications within 9–23 days with a total amount of 145–940 μg. Seven of eight patients required no further paracentesis during follow‐up or until death with a mean paracentesis‐free interval of 38 weeks (median = 21.5, range = 4–136). Tumor cell monitoring showed a complete elimination of tumor cells in ascites already at total doses as low as 40–140 μg. Clinical response with disappearance of ascites accumulation was seen in all patients, which was correlated with elimination of tumor cells (p = 0.0014). Severe adverse events were not observed. Clinically relevant side effects were fever, moderate abdominal pain and skin reactions. Intraperitoneal immunotherapy with trAb showed convincing efficacy in patients with malignant ascites. This treatment offers new therapeutic options for patients with peritoneal carcinomatosis. © 2005 Wiley‐Liss, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In an early clinical trial of patients with malignant ascites due to peritoneal carcinomatosis, administration of total doses of ertumaxomab as low as 40-140 μg led to complete elimination of tumor cells in ascites and disappearance of ascites accumulation in all patients.
“In an early clinical trial of patients with malignant ascites due to peritoneal carcinomatosis, administration of total doses of ertumaxomab as low as 40-140 μg lead to a complete elimination of tumor cells in ascites, and disappearance of ascites accumulation in all patients. 29”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [29]
Ertumaxomab possesses the same hybrid Fc portion as catumaxomab and displays the same efficiency in vitro.
“This triomab possesses the same hybrid Fc portion as catumaxomab, and displays the same efficiency in vitro. 29”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,240 · see citing works
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczyński, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 47,092 · see citing works
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657 · see citing works
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule.
Litvinov, S. V., Velders, M. P., Bakker, H. A. M., Fleuren, G. J., & Warnaar, S. O. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.125.2.437 · Cited by 525 · see citing works
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301 · see citing works
Clinical trials of antibody therapy
Glennie, M. J., & Johnson, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01669-8 · Cited by 290 · see citing works
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 275 · see citing works
Self-citationHeiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K., & Schildberg, F. W. (1995) · Nature Medicine · doi:10.1038/nm1095-1035 · Cited by 252 · see citing works
Self-citationLindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 3× · see citing works
“The intact antibodies not only activate T cells via CD3, but simultaneously bind and stimulate Fcc receptor type I and III1 accessory cells like e.g., monocytes/macrophages, NK cells and dendritic cells via their special Fc-region.4,6 trAb consist of the 2 potent and evolutionary related subclasses mouse IgG2a and rat…”
BackgroundMethodSelf-citationZeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204 · see citing works
Self-citationZeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189 · see citing works
Self-citationDecelerating growth and human breast cancer
Spratt, J. A., von Fournier, D., Spratt, J. S., & Weber, E. (1993) · Cancer · doi:10.1002/1097-0142(19930315)71:6 · Cited by 189 · see citing works
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Re, E. D., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187 · see citing works
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174 · see citing works
Self-citationMalignant ascites: a 2-year review from a teaching hospital
Parsons, S. L., Lang, M. W., & Steele, R. J. (1996) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(96)80009-6 · Cited by 117 · see citing works
Lohrisch, C. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90103-4 · Cited by 113 · see citing works
Risk of familial breast cancer
Anderson, D. E., & Badzioch, M. D. (1985) · Cancer · doi:10.1002/1097-0142(19850715)56:2 · Cited by 113 · see citing works
Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)
Riesenberg, R., Büchner, A., Pohla, H., & Lindhofer, H. (2001) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540104900711 · Cited by 96 · see citing works
Self-citationFreedman, R. S., Kudelka, A. P., Kavanagh, J. J., et al. (2000) · PubMed · Cited by 94 · see citing works
Malignant ascites: demographics, therapeutic efficacy and predictors of survival.
Mackey, J. R., & Venner, P. M. (1996) · PubMed · Cited by 68 · see citing works
Meng, J.-Y., Kataoka, H., Itoh, H., & Koono, M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200102)9999:9999 · Cited by 64 · see citing works
Kroesen, B., ter Haar, A., Spakman, H., Willemse, P. H. B., Sleijfer, D. T., de Vries, E. G. E., Mulder, N. H., Berendsen, H. H., Limburg, P. C., THE, T. H., et al. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01526797 · Cited by 64 · see citing works
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen, H., Manzke, O., Patel, B., et al. (1993) · PubMed · Cited by 62 · see citing works
Marmé, A., Strauß, G., Bastert, G., Grischke, E., & Moldenhauer, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10562 · Cited by 58 · see citing works
Sawyer, J. R., Husain, M., Pravdenkova, S. V., Krisht, A. F., & Al‐Mefty, O. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2 · Cited by 55 · see citing works
Two new trifunctional antibodies for the therapy of human malignant melanoma
Ruf, P., Jäger, M., Ellwart, J., Wosch, S., Kusterer, E., & Lindhofer, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11630 · Cited by 52 · see citing works
Self-citationBuckman, R. A., DeAngelis, C., Shaw, P. H., et al. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90084-v · Cited by 48 · see citing works
Demanet, C., Brissinck, J., Jonge, J. D., & Thielemans, K. (1996) · Blood · doi:10.1182/blood.v87.10.4390.bloodjournal87104390 · Cited by 47 · see citing works
The cellular basis of metastatic bone disease in patients with lung cancer
Cramer, S. F., Fried, L. E., & Carter, K. J. (1981) · Cancer · doi:10.1002/1097-0142(19811215)48:12 · Cited by 42 · see citing works
Lewis, L. D., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Guyre, P. M., Fanger, M. W., Curnow, R. T., Kaufman, P. A., & Ernstoff, M. S. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00355-0 · Cited by 26 · see citing works
Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models
Lindhofer, H., Menzel, H., Günther, W., Hültner, L., & Thierfelder, S. (1996) · Blood · doi:10.1182/blood.v88.12.4651.bloodjournal88124651 · Cited by 26 · see citing works
Self-citationHirte, H. W., Miller, D., Tonkin, K. S., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1996.4529 · Cited by 25 · see citing works
Validation of an Automated Enzyme Immunoassay for Interleukin-6 for Routine Clinical Use
Fraunberger, P., Pfeiffer, M. M., Cremer, P., et al. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.141 · Cited by 24 · see citing works
Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients.
Gebbia, V., Mannino, R., Di Dino, A., et al. (1994) · PubMed · Cited by 19 · see citing works
Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin
Maiche, A. G. (1994) · Anti-Cancer Drugs · doi:10.1097/00001813-199406000-00007 · Cited by 15 · see citing works
van Zanten-Przybysz, I., Molthoff, C. F. M., Roos, J. C., et al. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010401)92:1 · Cited by 13 · see citing works
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma.
Lorusso, Catino, A., Gargano, G., et al. (1994) · PubMed · Cited by 7 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, et al. Peritoneal carcinomatosis from non-gynecologic malignan- cies: results of the EVOCAPE 1 multicentric prospective study. Can- cer 2000;88:358-63.
- Jackson GL, Blosser NM. Intracavitary chromic phosphate (32P) col- loidal suspension therapy. Cancer 1981;48:2596-8.
- Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, Mantovani A. Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer 1985;56:294-301.
- Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993;71:2027-30.
- Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34.
Cited by
Sorted by citations
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257 · see citing works
Self-citationClinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76 · see citing works
Stanglmaier, M., Faltin, M., Ruf, P., Bodenhausen, A., Schröder, P., & Lindhofer, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23626 · Cited by 66 · see citing works
Self-citationBuhmann, R., Simoes, B., Stanglmaier, M., Yang, T., Faltin, M., Bund, D., Lindhofer, H., & Kolb, H.-J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.323 · Cited by 48 · see citing works
Self-citation
- Authors
- Heiss, M. M., Ströhlein, M. A., Jäger, M., Kimmig, R., Burges, A., Schoberth, A., Jauch, K., Schildberg, F., & Lindhofer, H.
- Affiliations
- Witten/Herdecke University (DE)
- Ludwig-Maximilians-Universität München (DE)
- LMU Klinikum (DE)
- Corresponding author
- Heiss, Markus M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-09-14
- Volume
- 117
- Issue
- 3
- Pages
- 435-443
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1979885539
- Cited by
- 117
- References
- 37
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 5
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- trifunctional antibody, bispecific antibodies, malignant ascites, peritoneal carcinomatosis, intraperitoneal immunotherapy, EpCAM, HER2/neu, tumor cell killing, adverse events
- MeSH terms
- Ascites, Humans, Immunotherapy, Leukocyte Count, Middle Aged, Peritoneal Neoplasms, T-Lymphocytes, Tumor Necrosis Factor-alpha, Cytokines, DNA Primers, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
